Trial · NCT03595917
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
NCT03595917, Phase 1, Recruiting, Marlise Luskin, MD
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML. Trials, record NCT03595917. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03595917
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- NCT number
- NCT03595917
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Marlise Luskin, MD
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
- Interventions
- ABL001, Dasatinib, Prednisone, Blinatumomab
- First posted
- 2018-07-23
- Last updated
- 2025-11-04
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum tolerated dose (MTD) of ABL001 | 42 Days | To define the maximum tolerated dose (MTD) of ABL001 for participants with BCR-ABL positive (BCR-ABL+) B-cell acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) in lymphoid blast crisis. |
| Secondary | Percentage for Participants Achieving Hematologic Remission | 28 Days | |
| Secondary | Percentage for Participants Achieving Hematologic Remission | 56 Days | |
| Secondary | Percentage for Participants Achieving Hematologic Remission | 85 Days | |
| Secondary | Percentage of participants achieving cytogenetic response | 28 Days | |
| Secondary | Percentage of participants achieving cytogenetic response | 56 Days | |
| Secondary | Percentage of participants achieving cytogenetic response | 85 Days | |
| Secondary | Percentage of participants achieving a minimal residual disease (MRD)-negative CR by flow cytometry | 85 Days | |
| Secondary | Percentage of participants achieving a minimal residual disease (MRD)-negative CR by flow cytometry | 28 Days | |
| Secondary | Percentage of participants achieving a minimal residual disease (MRD)-negative CR by flow cytometry | 56 Days |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03595917
GET https://conductscience.org/api/trials/v1/NCT03595917/registered